AMAL Therapeutics SA (AMAL) is a pre-clinical stage Swiss biotechnology company developing peptide/protein-based therapeutic vaccines with a focus on oncology. The Company’s therapeutic vaccines are based on its versatile proprietary technology platform called KISIMA®. AMAL’s lead program, ATP128 is a therapeutic protein vaccine for metastatic colorectal cancer, a leading cause of mortality. The program is expected to enter phase I clinical trials in 2019. In the longer term, the Company intends to develop a portfolio of program in other cancer indications.
